Aton Group Focuses on Preclinical Stage to Reduce 90% Pharmaceutical Failure Rate
Aton Group announces the deployment of its strategy focused on improving the predictability of preclinical trials, in response to a structural challenge in the pharmaceutical industry: over 90% of molecules tested in clinical trials fail before reaching the market.
The Stark Reality of Pharmaceutical R&D
According to a statement from Aton Group, out of 100 promising molecules initially, only a few (sometimes just one or two) make it to market. This reality raises questions about the relevance of experimental models that have been used for decades, often disconnected from the complexity of actual human physiology. The financial consequences are significant: each late-stage failure results in losses of several hundred million dollars and delays patient access to innovative therapies. Given this challenge, the preclinical trial phases are becoming the new strategic territory for pharmaceutical R&D.
Strategic Focus on Intelligent Preclinical Development
Aton Group is focusing its strategy on intelligent preclinical development, where experimental models incorporate human physiology to enhance the predictability of decisions. Aton reports that its subsidiaries have complementary expertise—translational pharmacology, human models, systemic analysis of biological data—coordinated around an ambition to reduce clinical risk from the earliest stages of development. The group views this opportunity as creating short-term value and generating significant synergies among its subsidiaries. Aton is currently engaged in several discussions with pharmaceutical and biotechnological players to integrate its solutions into preclinical trial programs.
